Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin

Nineteen patients with rheumatoid arthritis entered a double-blind cross-over study, comparing a new anti-inflammatory agent isoxepac, 200 mg three times daily, with aspirin 1.2 g three times daily. Eighteen patients completed 2-4 weeks treatment with each drug. The treatments were similar when assessed by measurement of joint pain, grip strength, morning stiffness, patients' global assessment and overall preference. Significantly fewer adverse effects were associated with isoxepac therapy when compared with aspirin therapy.